Skip to main content
NewslettersWatchlist

Xortx Therapeutics Inc(XRTX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low3.00
Day High3.23
Open:3.03
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
XORTX Welcomes New Member to the Board of Directors
GlobeNewswire
XORTX Announces Participation in Spring 2024 Investor Conferences
GlobeNewswire
XORTX Announces New Clinical Advisory Board Member
TheNewswire.com
XORTX: A Year of Milestones and Strategic Advancements as it Readies for a Registration Clinical Trial
GlobeNewswire
XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial
GlobeNewswire
XORTX Reprices Warrants Issued in Connection with Previous Private Placements
GlobeNewswire
XORTX Finalizes $2.7 Million Prospectus Supplement and Concurrent Private Placement for the Offering of Units
GlobeNewswire
XORTX Raises $2.5 Million Under Prospectus Supplement and Concurrent Private Placement for the Offering of Units
GlobeNewswire
XORTX Files an Amended and Restated Prospectus Supplement for the Offering of Units
GlobeNewswire
XORTX Announces $2 Million Public Offering
GlobeNewswire
XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease
GlobeNewswire
XORTX Announces US ATM Offering
GlobeNewswire
XORTX Meets Nasdaq Continued Listing Requirements
GlobeNewswire
XORTX Clarifies Timing for Share Consolidation
GlobeNewswire
XORTX Announces Share Consolidation
GlobeNewswire
XORTX Sponsored Study Presented at the American Society of Nephrology – Kidney Week 2023
GlobeNewswire
XORTX Announces Results of Special Meeting of Shareholders
GlobeNewswire
XORTX Announces Date for Rescheduled Special Meeting of Shareholders
GlobeNewswire
XORTX Announces Rescheduling of Special Meeting of Shareholders
GlobeNewswire
XORTX Reports that Independent Proxy Firm, ISS, Recommends Shareholders Vote for the Share Consolidation Resolution
GlobeNewswire
XORTX Calls Special Meeting of Shareholders
GlobeNewswire
XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology – Kidney Week 2023
GlobeNewswire
XORTX Announces Participation at Upcoming Investor Conferences
GlobeNewswire
XORTX Joins the Kidney Foundation and Kidney March
GlobeNewswire
XORTX Submits Orphan Drug Designation Application to the European Medicines Agency (EMA) to Treat Progressive Kidney Disease
GlobeNewswire
XORTX Appoints Chief Financial Officer
GlobeNewswire
XORTX Announces Results of Annual and Special Meeting of Shareholders
GlobeNewswire
XORTX Reminds Shareholders to Vote ahead of the Proxy Voting Deadline for the Company’s Upcoming Annual and Special Meeting of Shareholders
GlobeNewswire
XORTX Announces PKD Presentation
Globe Newswire
XORTX Announces Submission to European Medicines Agency
Globe Newswire
XORTX Announces Positive Topline Results from Pharmacokinetics Bridging Clinical Trial
Globe Newswire
XORTX Announces Pre-Phase 3 Meeting Request with US Food and Drug Administration (FDA)

Profile

XORTX Therapeutics Inc. is a pharmaceutical therapeutics company. It focused on developing therapies to treat progressive kidney disease. XORTX Therapeutics Inc. is based in CALGARY, Alberta.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.